ASX:BGT

Bio-Gene Technology (BGT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BGT Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Bio-Gene Technology alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Bio-Gene Technology Stock (ASX:BGT)

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University to refine the process for oil extraction; and with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for testing of Flavocide in grain storage. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

BGT Stock News Headlines

April 15, 2024 | msn.com

Bio-Rad announces collaboration agreement with oncocyte to commercialize transplant monitoring with droplet digital PCR

March 20, 2024 | msn.com

Biotech with links to Boston sets record price for new gene therapy for rare childhood disease

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 4, 2024 | forbes.com

Science Continues To Outpace Commercialization Of Cell And Gene Therapies

January 23, 2024 | wsj.com

Bio-Gene Technology Ltd.

December 13, 2023 | msn.com

3 Biotechs With Promising Gene Therapies in the Spotlight

December 11, 2023 | bizjournals.com

University of Pennsylvania Gene Therapy Program cuts staff by 25%, report says

December 4, 2023 | bizjournals.com

Durham biotech seeks partner to advance its gene therapy

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 30, 2023 | msn.com

Generation bio cuts 40% of staff in blow for non-viral gene therapy sector

November 28, 2023 | markets.businessinsider.com

Gene Bio Medical (GBM): Leading the Charge in Biotechnological Innovation and Global Healthcare Revolution

November 8, 2023 | businesswire.com

bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

November 8, 2023 | msn.com

Cell and gene therapy biotechs face access hurdles in Europe

November 6, 2023 | tmcnet.com

Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A

September 25, 2023 | msn.com

Are Gene Therapy Stocks The Market's Next Big Winners?

September 20, 2023 | msn.com

Pelican and Primordial Genetics merge to form biotech company Primrose Bio

September 18, 2023 | markets.businessinsider.com

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

August 28, 2023 | markets.businessinsider.com

Life Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering Transformation

August 15, 2023 | msn.com

BTIG Maintains Mustang Bio (MBIO) Buy Recommendation

August 11, 2023 | wsj.com

Senior Personal Technology Columnist, The Wall Street Journal

August 1, 2023 | bizjournals.com

Gene therapy startup founded by Pfizer, Biogen vet to shut down

June 5, 2023 | finance.yahoo.com

Form Bio Announces FORMsightAI, a Breakthrough AI Solution Set for Predicting and Optimizing Cell & Gene Therapy Manufacturability

May 24, 2023 | bizjournals.com

In another mega-round, ElevateBio raises $401M for cell and gene therapy

May 19, 2023 | benzinga.com

Scout Bio to Present at Upcoming Gene and Cell Therapy Summit

May 10, 2023 | businesswire.com

Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases

May 4, 2023 | marketwatch.com

Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering

May 2, 2023 | marketwatch.com

Gene Engineered Subunit Vaccine Market Size 2023-2031 Industrial Regions by Absolute Reports | with [85 Pages]

See More Headlines

Receive BGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Gene Technology and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:BGT
CUSIP: N/A
CIK: N/A
Web: www.bio-gene.com.au
Phone: 61 3 9628 4178
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -65.75%
Return on Assets: -35.65%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 7.08
Quick Ratio: 6.72

Sales & Book Value

Annual Sales: $445,726.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 7.04
Book Value: A$0.02 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 201,360,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.35

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Roger McPherson B.Bus
C.P.A., CPA, GAICD, Interim CFO & Company Secretary
Mr. Peter Donald May AFA1M
AFAIM, GAICD, M.B.A., MBA, Executive Director of Research & Development and Executive Director
Mr. Timothy Owen Grogan B.Sc.
LLB, MD, CEO & Director

Key Competitors

View All Competitors

Insiders

This page (ASX:BGT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bio-Gene Technology (BGT) Stock Price, News & Analysis

About Bio-Gene Technology Stock (ASX:BGT)

BGT Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info